Literature DB >> 1930199

Separation of the two domains of human mucus proteinase inhibitor: inhibitory activity is only located in the carboxy-terminal domain.

I Van-Seuningen1, M Davril.   

Abstract

Human mucus proteinase inhibitor is a two-domain protein which inactivates bovine trypsin and chymotrypsin, leukocyte elastase and cathepsin G. In order to localize the site(s) responsible for these inhibitory activities, the two domains were isolated after specific cleavage of the Asp49-Pro50 bond following mild acid treatment of the bronchial inhibitor. The carboxy-terminal domain was active against leukocyte elastase, trypsin and chymotrypsin whereas the amino-terminal domain, which contained a putative antitryptic active site, was devoid of activity. This implicates that, in the whole molecule, the inhibitory activity region is localized only in the carboxy-terminal domain.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1930199     DOI: 10.1016/0006-291x(91)91755-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

Review 1.  Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor.

Authors:  Stergios Doumas; Alexandros Kolokotronis; Panagiotis Stefanopoulos
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

2.  Antibacterial activity of antileukoprotease.

Authors:  P S Hiemstra; R J Maassen; J Stolk; R Heinzel-Wieland; G J Steffens; J H Dijkman
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 3.  Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidants.

Authors:  Megan Meyer; Ilona Jaspers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-04-17       Impact factor: 5.464

Review 4.  Use of modulators of airways inflammation in patients with CF.

Authors:  Clement L Ren
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

5.  Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells.

Authors:  Nick Devoogdt; Gholamreza Hassanzadeh Ghassabeh; Jing Zhang; Lea Brys; Patrick De Baetselier; Hilde Revets
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

6.  Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases.

Authors:  Marie-Louise Zani; Kévin Baranger; Nicolas Guyot; Sandrine Dallet-Choisy; Thierry Moreau
Journal:  Protein Sci       Date:  2009-03       Impact factor: 6.725

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.